In order to facilitate the translation of these targeting strategies, we developed HIFi‐CCS and HIFi‐BCS, two novel, biologically derived, compact HIFα transcript signatures able to predict overall survival and metastatic dissemination in colon and breast cancer patients, potentially amenable for stratification and identification of patients that are more likely to benefit from LDM alone or in combination with HIFα antagonists [e.g., HIF‐2α antagonists such as PT‐2385, currently under phase I trials in advanced clear cell renal cell carcinoma (Courtney et al, 2018)]. Here, EPAS1 is linked to breast cancer.